Chinook Therapeutics, Inc. is a Clinical Stage Biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases. The headquarters is in USA.
Novartis acquired Chinook Therapeutics Inc. for 3.5 billion USD in 2023.
Chinook’s pipeline includes two late-stage assets in clinical development to treat Immunoglobulin A Nephropathy (IgAN), atrasentan and zigakibart (BION-1301), as well as earlier stage research and development programs. Atrasentan, an oral endothelin A receptor antagonist (ERA) currently in Phase 3 development for IgAN with a pivotal readout expected in Q4 2023, has shown significant reductions in proteinuria.